美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NewcelX Ltd.

2.40

-0.0300-1.23%

成交量：771.00

成交額：1,850.40

市值：1,094.02萬

市盈率：-0.56

高：2.40

開：2.40

低：2.40

收：2.43

52周最高：30.80

52周最低：1.89

股本：455.84萬

流通股本：455.84萬

量比：1.45

換手率：0.02%

股息：- -

股息率：- -

每股收益(TTM):-4.3226

每股收益(LYR):-1.7386

淨資產收益率：--

總資產收益率：-155.19%

市淨率：-0.80

市盈率(LYR):-1.38

資料載入中...

總覽公司新聞資訊公告

Newcelx攜手Eledon製藥推進Ncel-101項目開啓1型糖尿病治療新篇章

Newcelx Ltd.盤中異動早盤急速拉升5.48%

Newcelx Ltd.盤中異動臨近收盤股價大漲5.11%報2.78美元

Newcelx Ltd.盤中異動股價大漲6.31%

Newcelx Ltd.盤中異動早盤股價大漲5.93%報2.50美元

Newcelx Ltd.盤中異動早盤股價大漲5.26%報2.60美元

Newcelx Ltd.盤中異動漲7.75% 振幅達22.01%

NewcelX任命瑞士糖尿病創新巨頭Julien Boisdron博士加入科學顧問委員會

Newcelx Ltd.盤中異動早盤股價大跌5.14%報2.03美元

NewcelX有限公司通過任命Barrow神經科學研究所首席醫療官Jeremy Shefner博士增強科學顧問委員會

NewcelX 在與 NLS Pharmaceutics Ltd. 合併後提供業務和戰略路線圖更新

NLS Pharmaceutics：在與Kadimastem合併後，合併公司將繼續推進Itol-102項目

NLS Pharmaceutics Ltd. 宣佈進行1比10的反向股票拆分並更改名稱，以配合與Kadimastem的擬議合併

NLS Pharmaceutics與Kadimastem宣佈合併交易的重大前提條件已完成以及Kadimastem股票的退市日期

NLS Pharmaceutics與Kadimastem宣佈Kadimastem與Targetgene之間的戰略合作，以推動下一代基因編輯細胞療法

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NCEL/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":2.4,"timestamp":1774532100002,"preClose":2.43,"halted":0,"volume":771,"delay":0,"changeRate":-0.01234567901234578,"floatShares":4558400,"shares":4558400,"eps":-4.322621,"marketStatus":"交易中","change":-0.03,"latestTime":"03-26 09:54:32 EDT","open":2.4,"high":2.4,"low":2.4,"amount":1850.3999999999999,"amplitude":0,"askPrice":2.43,"askSize":2,"bidPrice":2.36,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.322621,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":2.43,"preHourTrading":{"tag":"盘前","latestPrice":2.49,"preClose":2.43,"latestTime":"08:00 EDT","volume":53,"amount":131.97,"timestamp":1774526402967,"change":0.06,"changeRate":0.024691,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.43,"preClose":2.43,"latestTime":"18:14 EDT","volume":6,"amount":14.67,"timestamp":1774476880330,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.450227},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":4558400,"roa":"-155.19%","roe":"--","lyrEps":-1.738588,"volumeRatio":1.450227,"shares":4558400,"dividePrice":0,"high":2.4,"amplitude":0,"preClose":2.43,"low":2.4,"week52Low":1.89,"pbRate":"-0.80","week52High":30.799,"institutionHeld":0,"latestPrice":2.4,"committee":0.960784,"eps":-4.322621,"divideRate":0,"volume":771,"delay":0,"ttmEps":-4.322621,"open":2.4,"prevYearClose":1.9,"prevWeekClose":2.37,"prevMonthClose":2.9,"prevQuarterClose":1.9,"fiveDayClose":2.45,"twentyDayClose":2.87,"sixtyDayClose":2.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-03-25","current":-0.562159,"percent":0.886598,"low":-2.085416,"twenty":-0.836568,"median":-0.625846,"eighty":-0.574551,"high":-0.442896,"avg":-0.702482,"sd":0.217071,"marketCap":11031274},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117},{"date":"2026-02-13","current":-0.627168,"twenty":-0.875612,"median":-0.627168,"eighty":-0.572325,"marketCap":12717874},{"date":"2026-02-20","current":-0.632256,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"marketCap":12581123},{"date":"2026-02-27","current":-0.656951,"twenty":-0.860299,"median":-0.626808,"eighty":-0.575926,"marketCap":13082544},{"date":"2026-03-06","current":-0.638142,"twenty":-0.856719,"median":-0.630594,"eighty":-0.581513,"marketCap":12854625},{"date":"2026-03-13","current":-0.639458,"twenty":-0.843011,"median":-0.628376,"eighty":-0.587749,"marketCap":12717874},{"date":"2026-03-20","current":-0.559522,"twenty":-0.837754,"median":-0.626853,"eighty":-0.587749,"marketCap":11168026},{"date":"2026-03-25","current":-0.551502,"twenty":-0.836568,"median":-0.625846,"eighty":-0.574551,"marketCap":11031274}],"updateTime":1774519506468},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1175524782","title":"Newcelx攜手Eledon製藥推進Ncel-101項目 開啓1型糖尿病治療新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1175524782","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175524782?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 19:03","pubTimestamp":1773054236,"startTime":"0","endTime":"0","summary":"生物技术公司Newcelx宣布与Eledon制药达成战略合作，双方将共同推进Ncel-101项目在1型糖尿病治疗领域的临床开发。这一合作标志着两家企业在细胞治疗领域的深度协同，有望为自身免疫性疾病患者带来突破性治疗方案。Ncel-101作为Newcelx的核心在研项目，其创新机制针对1型糖尿病的病理基础展开干预。通过整合Eledon制药在免疫调节领域的专有技术平台，该项目有望加速实现从实验室到临床的转化。业界观察人士指出，此次合作或将重塑糖尿病治疗的研发格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2614773552","title":"Newcelx Ltd.盤中異動 早盤急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614773552?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 22:57","pubTimestamp":1771945028,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时57分，Newcelx Ltd.股票出现异动，股价快速拉升5.48%。截至发稿，该股报2.79美元/股，成交量332股，换手率0.01%，振幅0.00%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为0.37%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224225708a71a63e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224225708a71a63e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2609517287","title":"Newcelx Ltd.盤中異動 臨近收盤股價大漲5.11%報2.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609517287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609517287?lang=zh_tw&edition=fundamental","pubTime":"2026-02-07 04:36","pubTimestamp":1770410218,"startTime":"0","endTime":"0","summary":"北京时间2026年02月07日04时36分，Newcelx Ltd.股票出现波动，股价大幅上涨5.11%。截至发稿，该股报2.78美元/股，成交量9751股，换手率0.21%，振幅4.55%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为1.43%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207043659a485e10a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207043659a485e10a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2605450954","title":"Newcelx Ltd.盤中異動 股價大漲6.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605450954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605450954?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 00:45","pubTimestamp":1769100344,"startTime":"0","endTime":"0","summary":"北京时间2026年01月23日00时45分，Newcelx Ltd.股票出现波动，股价急速拉升6.31%。截至发稿，该股报2.57美元/股，成交量3.0889万股，换手率0.68%，振幅5.37%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为0.90%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123004544953df42f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123004544953df42f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2605787451","title":"Newcelx Ltd.盤中異動 早盤股價大漲5.93%報2.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605787451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605787451?lang=zh_tw&edition=fundamental","pubTime":"2026-01-21 00:01","pubTimestamp":1768924914,"startTime":"0","endTime":"0","summary":"北京时间2026年01月21日00时01分，Newcelx Ltd.股票出现波动，股价急速上涨5.93%。截至发稿，该股报2.50美元/股，成交量3.5072万股，换手率0.77%，振幅4.66%。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.62%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121000155a7314055&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121000155a7314055&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2603642466","title":"Newcelx Ltd.盤中異動 早盤股價大漲5.26%報2.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642466","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642466?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 23:06","pubTimestamp":1768403216,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日23时06分，Newcelx Ltd.股票出现波动，股价快速拉升5.26%。截至发稿，该股报2.60美元/股，成交量2.2568万股，换手率0.50%，振幅9.24%。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.16%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011423065697a1d39c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011423065697a1d39c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2601742898","title":"Newcelx Ltd.盤中異動漲7.75% 振幅達22.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601742898","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601742898?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 22:36","pubTimestamp":1767623778,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时36分，Newcelx Ltd.股票出现波动，股价大幅上涨7.75%。截至发稿，该股报2.25美元/股，成交量47.5385万股，换手率10.43%，振幅22.01%。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.58%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010522361897a10d76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010522361897a10d76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"1122151526","title":"NewcelX任命瑞士糖尿病創新巨頭Julien Boisdron博士加入科學顧問委員會","url":"https://stock-news.laohu8.com/highlight/detail?id=1122151526","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122151526?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 20:07","pubTimestamp":1767614836,"startTime":"0","endTime":"0","summary":"NewcelX Ltd.宣布，瑞士糖尿病创新领域的领军人物Julien Boisdron博士已正式加入其科学顾问委员会。这一重要人事任命将显著增强公司在糖尿病治疗领域的研发实力。Boisdron博士在大型制药企业积累的丰富经验，有望为NewcelX的技术创新和战略发展注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2595874370","title":"Newcelx Ltd.盤中異動 早盤股價大跌5.14%報2.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595874370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595874370?lang=zh_tw&edition=fundamental","pubTime":"2025-12-31 00:09","pubTimestamp":1767110949,"startTime":"0","endTime":"0","summary":"北京时间2025年12月31日00时09分，Newcelx Ltd.股票出现异动，股价大幅下跌5.14%。截至发稿，该股报2.03美元/股，成交量2.3783万股，换手率0.52%，振幅3.97%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.78%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231000910953bd57a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231000910953bd57a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"1143544598","title":"NewcelX有限公司通過任命Barrow神經科學研究所首席醫療官Jeremy Shefner博士增強科學顧問委員會","url":"https://stock-news.laohu8.com/highlight/detail?id=1143544598","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143544598?lang=zh_tw&edition=fundamental","pubTime":"2025-11-17 20:02","pubTimestamp":1763380947,"startTime":"0","endTime":"0","summary":"NewcelX有限公司通过任命Barrow神经科学研究所首席医疗官Jeremy Shefner博士增强科学顾问委员会","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"1199796406","title":"NewcelX 在與 NLS Pharmaceutics Ltd. 合併後提供業務和戰略路線圖更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1199796406","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199796406?lang=zh_tw&edition=fundamental","pubTime":"2025-11-03 21:27","pubTimestamp":1762176430,"startTime":"0","endTime":"0","summary":"NewcelX 在与 NLS Pharmaceutics Ltd. 合并后提供业务和战略路线图更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"1166589130","title":"NLS Pharmaceutics：在與Kadimastem合併後，合併公司將繼續推進Itol-102項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1166589130","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166589130?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 19:22","pubTimestamp":1761736977,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics：在与Kadimastem合并后，合并公司将继续推进Itol-102项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4007","NLSP"],"gpt_icon":0},{"id":"1171878787","title":"NLS Pharmaceutics Ltd. 宣佈進行1比10的反向股票拆分並更改名稱，以配合與Kadimastem的擬議合併","url":"https://stock-news.laohu8.com/highlight/detail?id=1171878787","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171878787?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 18:00","pubTimestamp":1761732022,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics Ltd. 宣布进行1比10的反向股票拆分并更改名称，以配合与Kadimastem的拟议合并。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NCEL","NLSPW","NLSP"],"gpt_icon":0},{"id":"1176769345","title":"NLS Pharmaceutics與Kadimastem宣佈合併交易的重大前提條件已完成以及Kadimastem股票的退市日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1176769345","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176769345?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 15:54","pubTimestamp":1761724465,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics与Kadimastem宣布合并交易的重大前提条件已完成，并确认Kadimastem股票的退市日期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NCEL","NLSP"],"gpt_icon":0},{"id":"1131118792","title":"NLS Pharmaceutics與Kadimastem宣佈Kadimastem與Targetgene之間的戰略合作，以推動下一代基因編輯細胞療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1131118792","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131118792?lang=zh_tw&edition=fundamental","pubTime":"2025-10-27 19:02","pubTimestamp":1761562934,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics与Kadimastem宣布Kadimastem与Targetgene之间的战略合作，以推动下一代基因编辑细胞疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NCEL","NLSPW","NLSP"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}